Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 3:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Experimental: Primary Cohort Clear all
Recruiting Phase 1Phase 2 Interventional

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions
TRX319, Bendamustine
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Terminated Phase 1 Interventional

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

NCT05831995
View directory record Official record
Conditions
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
Interventions
ABM-168
Drug
Lead sponsor
ABM Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Francisco, California • Indianapolis, Indiana • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 22, 2026, 3:01 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

NCT00546260
View directory record Official record
Conditions
Myocardial Infarction
Interventions
placebo, PRT060128 Potassium
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Tallahassee, Florida • Des Moines, Iowa • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Terminated Phase 1 Interventional Results available

MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03585764
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
MOv19-BBz CAR T cells, Alpha Folate Receptor expression test
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 22, 2026, 3:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

NCT05774899
View directory record Official record
Conditions
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Interventions
CB-103, Abemaciclib, Lenvatinib
Drug
Lead sponsor
Michael J. Dennis, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Recruiting Not applicable Interventional

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

NCT07062471
View directory record Official record
Conditions
Carotid Artery Calcification, Carotid Artery Diseases
Interventions
Carotid Intravascular Lithotripsy (IVL)
Device
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
25
States / cities
Little Rock, Arkansas • Rancho Mirage, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

NCT05972720
View directory record Official record
Conditions
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Interventions
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
Drug
Lead sponsor
CARGO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 22, 2026, 3:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447
View directory record Official record
Conditions
Ovarian Cancer Recurrent
Interventions
Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication, Pembrolizumab, Gemcitabine, Pegylated liposomal doxorubicin, MK-2010
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Active, not recruiting Not applicable Interventional

Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment

NCT05039554
View directory record Official record
Conditions
Opioid-use Disorder, Chronic Pain
Interventions
Acceptance and commitment therapy, Valera Smartphone Application, Treatment as Usual
Behavioral · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation

NCT07438327
View directory record Official record
Conditions
Aortic Aneurysm, Aortic Aneurysm Abdominal, Aortic Aneurysm and Dissection, Aortic Aneurysm, Thoracoabdominal
Interventions
Aorta AIM Automated Measurement, Expert Radiologist Manual Measurement
Diagnostic Test
Lead sponsor
Aiatella Oy
Industry
Eligibility
22 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

NCT06008860
View directory record Official record
Conditions
COVID-19
Interventions
Experimental: Primary Cohort, Placebo Comparator: Primary Cohort - Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 22, 2026, 3:01 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

NCT02842125
View directory record Official record
Conditions
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Interventions
Ad-P53, Xeloda, Keytruda, Opdivo
Drug
Lead sponsor
MultiVir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 22, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Results available

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT04950764
View directory record Official record
Conditions
Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Interventions
Seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Enrolling by invitation Phase 3 Interventional

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

NCT04360265
View directory record Official record
Conditions
Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Interventions
No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccine Responsiveness After CAR-T Cell Therapy

NCT04410900
View directory record Official record
Conditions
B-Cell Neoplasm
Interventions
Wistar Rabies Virus Strain PM-1503-3M Vaccine, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 22, 2026, 3:01 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 22, 2026, 3:01 PM EDT
Terminated Phase 1 Interventional Results available

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

NCT02948426
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Autologous Monocytes + ACTIMMUNE + SYLATRON
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Completed Phase 1 Interventional Results available

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

NCT01772004
View directory record Official record
Conditions
Solid Tumors
Interventions
Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
53
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Sep 22, 2026, 3:01 PM EDT
Enrolling by invitation No phase listed Observational

Federated Learning for Point-of-Care Cardiac Ultrasound

NCT07800962
View directory record Official record
Conditions
Ventricular Dysfunction, Left, Ventricular Function, Left, Echocardiography, Ultrasonography, Point-of-Care Systems, Heart Function Tests, Stroke Volume, Federated Learning, Machine Learning, Artificial Intelligence (AI), Deep Learning, Neural Networks, Computer, Image Interpretation, Computer-Assisted, Diagnosis, Computer-Assisted, Sensitivity and Specificity, ROC Curve
Interventions
Focused Cardiac Point-of-Care Ultrasonography, FL-POCUS Federated Machine-Learning Analysis System
Diagnostic Test · Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

NCT06561425
View directory record Official record
Conditions
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell
Interventions
GLPG5101
Genetic
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

FreshStart for Health Study

NCT07815756
View directory record Official record
Conditions
Food Insecurity
Interventions
Produce prescription, Nutrition education
Behavioral
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
4
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 22, 2026, 3:01 PM EDT
Recruiting No phase listed Observational

Genomic Profiling in Cancer Patients

NCT01775072
View directory record Official record
Conditions
Solid Tumors, Hematologic Cancers
Interventions
molecular profiling of tumors, Clinical Germline Analysis
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
18
States / cities
Bridgeport, Connecticut • Hartford, Connecticut • Norwalk, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 22, 2026, 3:01 PM EDT